Village development committee (Nepal)

PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

Retrieved on: 
Tuesday, February 14, 2023
Mental Health, Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Allopregnanolone, LSE, Social anxiety, Woman, Therapy, Village development committee (Nepal), PPD, PureTech Health, Patient, Clinical trial, Depression, Anxiety, PRTC, GABAA, Multimedia, R, Pharmaceutical industry, Vaccine, Glyph

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that it will advance LYT-300 (oral allopregnanolone) for the potential treatment of anxiety disorders and postpartum depression (PPD).

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that it will advance LYT-300 (oral allopregnanolone) for the potential treatment of anxiety disorders and postpartum depression (PPD).
  • An open-label, Phase 2a, proof-of-concept clinical trial in women with PPD is expected to initiate in the second half of 2023.
  • “Using our proprietary Glyphâ„¢ platform, we have made natural allopregnanolone orally bioavailable without permanently chemically modifying the natural neurosteroid.
  • It has demonstrated a rapid onset of action for the treatment of depression, as well as the potential to treat other neurological conditions, including anxiety, but its poor oral bioavailability has limited its therapeutic potential.